BriaCell Therapeutics Corp. (BCT.TO)
5.91
-0.01
(-0.17%)
CAD |
TSX |
Sep 18, 16:00
BriaCell Therapeutics Enterprise Value : 10.93M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 10.93M |
| September 17, 2026 | 11.00M |
| September 16, 2026 | 4.185M |
| September 15, 2026 | 3.750M |
| September 14, 2026 | 4.185M |
| September 11, 2026 | 4.620M |
| September 10, 2026 | 4.257M |
| September 09, 2026 | 4.692M |
| September 08, 2026 | 3.242M |
| September 04, 2026 | 3.822M |
| September 03, 2026 | 3.387M |
| September 02, 2026 | 3.967M |
| September 01, 2026 | 4.692M |
| August 31, 2026 | 4.112M |
| August 28, 2026 | 5.708M |
| August 27, 2026 | 5.49M |
| August 26, 2026 | 8.825M |
| August 25, 2026 | 5.345M |
| August 24, 2026 | 3.025M |
| August 21, 2026 | 8.390M |
| August 20, 2026 | 7.810M |
| August 19, 2026 | 7.593M |
| August 18, 2026 | 3.242M |
| August 17, 2026 | 2.155M |
| August 14, 2026 | 2.372M |
| Date | Value |
|---|---|
| August 13, 2026 | 2.880M |
| August 12, 2026 | 2.445M |
| August 11, 2026 | 2.735M |
| August 10, 2026 | 2.300M |
| August 07, 2026 | 4.837M |
| August 06, 2026 | 3.242M |
| August 05, 2026 | 3.822M |
| August 04, 2026 | 2.227M |
| July 31, 2026 | 3.025M |
| July 30, 2026 | 5.055M |
| July 29, 2026 | 3.097M |
| July 28, 2026 | 3.315M |
| July 27, 2026 | 4.620M |
| July 24, 2026 | 4.547M |
| July 23, 2026 | 5.925M |
| July 21, 2026 | 6.07M |
| July 20, 2026 | 4.982M |
| July 17, 2026 | 6.215M |
| July 16, 2026 | 6.795M |
| July 15, 2026 | 8.100M |
| July 14, 2026 | 5.925M |
| July 13, 2026 | 6.723M |
| July 10, 2026 | 8.535M |
| July 09, 2026 | 5.562M |
| July 08, 2026 | 6.288M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kane Biotech, Inc. | 7.260M |
| Quest PharmaTech, Inc. | 5.214M |
| Vaxil Bio Ltd. | 0.1137M |
| Waverley Pharma, Inc. | 4.099M |
| Goldcoast Resource Corp. | 1.580M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.920M |
| Total Expenses (Quarterly) | 9.820M |
| EPS Diluted (Quarterly) | -1.354 |
| Earnings Yield | -285.4% |
| Normalized Earnings Yield | -291.32 |